Search results for "pancreatic cancer"

Risk of pancreatic malignancy and mortality in branch-duct IPMNs undergoing surveillance: A systematic review and meta-analysis

2016

Abstract Background Safety of non-operative management for low-risk branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs) is debated. Aim To perform a systematic review/meta-analysis to determine their risk of developing pancreatic malignancy and of pancreatic malignancy-related deaths. Methods A MEDLINE search was performed and methodology was based on PRISMA statement. Incidence rates of overall pancreatic malignancy, malignant BD-IPMN, IPMN-distinct PDAC, and of pancreatic malignancy-related death rates were calculated by dividing the total number of events by the total number of person-years (pyrs) of follow-up. Heterogeneity was determined by I2 statistic. Results 20 studies …

Jakość życia chorych na zaawansowanego raka trzustki

2021

Pancreatic cancer is one of the most common malignancies with poor prognosis and high mortality. Advanced-stage disease at diagnosis and the dominant clinical symptoms significantly deteriorate the quality of life. The paper presents an analysis of the results of quality of life studies in patients with locally advanced and metastatic pancreatic cancer, as well as the relationship between therapeutic decisions and quality of life indicators. It has been shown that the initial assessment of life quality can have prognostic value. Appropriate symptomatic treatment of patients with advanced pancreatic cancer improves the quality of life, increases the compliance and prolongs survival. The asse…

Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review.

2014

Abstract Background/objectives Cachexia affects ∼80% of pancreatic cancer patients. An international consensus defines cachexia as an ongoing loss of skeletal muscle mass (sarcopenia) with or without loss of fat, which impairs body functioning and cannot be reversed by conventional nutritional measures. Weight loss percentage and elevated inflammation markers have been employed to define this condition earlier. This review aimed to assess the prevalence and consequences of cachexia and sarcopenia on survival in patients with pancreatic ductal adenocarcinoma. Methods The systematic review was performed by searching the articles with preset terms published in PubMed and Cochrane Database unti…

The management of locally advanced pancreatic cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 14…

2014

T. Seufferlein1, J. L. Van Laethem2, E. Van Cutsem3*, J. D. Berlin4, M. Buchler5, A. Cervantes6, K. Haustermans3, M. Hidalgo7, E. M. O’Reilly8, C. Verslype3, W. Schmiegel9 & P. Rougier10 Department of Internal Medicine I, University of Ulm, Ulm, Germany; Department of Gastroenterology, Hopitaux Universitaires Bordet-Erasme, Brussels; Digestive Oncology and Radiation Oncology, University Hospitals and KU Leuven, Leuven, Belgium; Department of Medicine, Vanderbilt University, Nashville, USA; Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany; Department of Hematology and Medical Oncology, INCLIVA, University of Valencia, Valencia; Gastro…

The management of metastatic pancreatic cancer: expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, B…

2013

Cancer of Exocrine Pancreas

2021

Pancreatic adenocarcinoma represents today a real challenge for oncologists all around the world: it is the 11th most common cancer worldwide, and the 7th deadliest, with a steadily increasing number of new cases every year. Many risk factors, both environmental and genetic, have been identified, the most important of which are excessive body weight, diabetes, and smoking; also, new diagnostic techniques, such as spiral TC, MRCP, and EUS, have improved the ability to diagnose this disease at an early stage. Nevertheless, pancreatic cancer is a silent disease, with few or no symptoms and signs until late stages: the vast majority of patients are inoperable at the time of diagnosis, with eith…

Pancreatic cancer trends in Europe: epidemiology and risk factors

2019

Pancreatic cancer is the 12th most common cancer worldwide and the seventh leading cause of cancer-related deaths worldwide. However, it is the seventh most common cancer in Europe. The estimated number of cases of pancreatic cancer worldwide in 2018 was 458,918 with a male to female ratio of 1:1.13. Among those 458,918 patients, 132,559 cases were found in Europe. Rates of pancreatic cancer are 3–4 times higher in the developed world. With incidence and mortality rates being very close, pancreatic cancer is considered one of the deadliest of all cancers. Lifestyle in developed nations, including the rise in physical inactivity and obesity, tobacco smoking, consumption of alcohol, dietary f…

PREDICTIVE FACTORS FOR MORBIDITY, MORTALITY AND SURVIVAL AFTER PANCREATICODUODENECTOMY

Transcript profiling identifies novel key players mediating the growth inhibitory effect of NS-398 on human pancreatic cancer cells

2010

Pancreatic cancer is one of the most aggressive human malignancies with an increasing incidence worldwide. Despite an increase in the number of systemic treatments available for pancreatic cancer, the impact of therapy on the clinical course of the disease has been modest, underscoring an urgent need for new therapeutic options. Although selective cyclooxygenase-2 inhibitors have been demonstrated to have cancer-preventive effects, the mechanism of their effects is not clearly known. Moreover, there have been no unbiased studies to identify novel molecular targets of NS-398 regarding pancreatic cancer. Here we undertook a gene expression profiling study to identify novel molecular targets m…

New cell lines of gastric and pancreatic cancer: distinct morphology, growth characteristics, expression of epithelial and immunoregulatory antigens.

1995

Two new cell lines from stomach cancers and one from a pancreatic carcinoma are presented. MZ-GC-1 was established from a hepatic metastasis of a well differentiated gastric adenocarcinoma. MZ-GC-2 was derived from ascites induced by a poorly differentiated gastric adenocarcinoma. MZ-PC-1 originated from the pleural effusion of a moderately well differentiated pancreatic ductal adenocarcinoma. MZ-GC-1 cells were adherent and partially polarized, connected tightly via desmosomes. In contrast MZ-GC-2 cells consisted of slightly adherent or floating subpopulations and displayed no desmosomes. MZ-PC-1 cells were adherent and showed polarized growth, connected by apical junctional complexes. Cel…